Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIG-1 phase 3 strategy trial in adult acute myeloid leukemia
2014-000699-24Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Jan 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of idarubicin, daunorubicin, cytarabine, mycophenolic acid and vosaroxin in acute myeloid leukemia (AML) (6 arms), sponsored by Centre Hospitalier Universitaire d'Angers. Started Jan 2015; status: active.
02
Drugs
idarubicindaunorubicincytarabinemycophenolic acidvosaroxin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-000699-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000699-24.